At the corporate briefing on the 25th, BioGend Therapeutics Chairman Te-Li Chen announced that the company’s operations are experiencing rapid growth, with several core technologies entering the harvest stage. Among them, results from the bone growth factor clinical trial will be unblinded in the third quarter, while licensing negotiations for RevoCart are expected to be completed within the year.
BioGend’s performance continues to improve. Revenue for July reached NT$24 million, with a pre-tax net profit of NT$650,000, marking a turnaround from losses to profitability. Cumulative revenue for the first seven months totaled NT$124 million, a 41% year-on-year increase. However, the company posted a net loss per share of NT$0.46 after tax in the first half of the year.
Chen explained that the composite medical device Osteoinductive Factor with Beta-Tricalcium Phosphate (OIF/B-TCP) is expected to replace current standard therapies, eliminating the risks associated with autologous bone grafting. Results from the Taiwan-U.S. clinical trials targeting moderate to severe open tibial fractures are expected in Q3. Based on these outcomes, the company will assess whether to advance to Phase III clinical trials. Together with results from prior non-union fracture trials, BioGend plans to push forward licensing discussions with leading international companies.
According to market research, the global bone regeneration market is valued at several billion U.S. dollars annually. With its non-animal origin, high safety profile, and cost advantages, OIF is positioned to penetrate the market and potentially replace existing products.
In addition, BioGend’s joint cartilage regeneration product RevoCart is expected to complete hospital admissions at all medical centers by year-end. It has already been adopted by over 170 physicians, with nearly 1,000 patients treated in Taiwan.
Internationally, the first procedure in Malaysia was successfully completed, and certification was recently obtained in Hong Kong, enabling product expansion into the Greater Bay Area. Negotiations with distributors in Singapore are ongoing, while regulatory approval in Vietnam is also expected soon. BioGend has already engaged in multiple rounds of discussions with potential U.S. licensing partners, with an agreement likely to be finalized within the year—poised to become a key driver of long-term profitability.
Looking ahead, Chen emphasized three major goals for the second half of the year:
- Publish the final report of the Taiwan-U.S. OIF clinical trial and prepare for Phase III trials.
- Complete the licensing agreement for RevoCart in the U.S., paving the way for entry into the North American market.
- Maintain double-digit revenue growth in 2025, strengthening the company’s ability to self-finance operations.
Resource: 博晟7月由虧轉盈 骨生長因子臨床試驗第三季解盲
